Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth
Shineco (NASDAQ: SISI) has formed a strategic partnership with Singapore-based BICC Pte Ltd to advance their blockchain-based cell asset ecosystem. The collaboration focuses on implementing and redeeming "on-chain cell assets" across multiple institutions, marking a transition from technical integration to real-world applications.
The partnership builds on Shineco's previous initiatives, including establishing a Cell Digital Division and acquiring a 51% stake in Xi'an Dong'ao Health Management. Plus Me will provide digital management for Shineco's stem cells on Ethereum, while BICC will integrate its iPSC stem cell storage services into Shineco's blockchain system. The collaboration leverages BICC's network of 3,000+ sales representatives and their expertise in wound-healing solutions, cell banking, and exosome delivery technology.
Shineco (NASDAQ: SISI) ha stretto una partnership strategica con BICC Pte Ltd, con sede a Singapore, per sviluppare il loro ecosistema di asset cellulari basato su blockchain. La collaborazione è incentrata sull'implementazione e il riscatto di "on-chain cell assets" tra diverse istituzioni, segnando il passaggio dall'integrazione tecnica ad applicazioni nel mondo reale.
La partnership si basa sulle iniziative precedenti di Shineco, tra cui la creazione di una Cell Digital Division e l'acquisizione di una quota del 51% in Xi'an Dong'ao Health Management. Plus Me fornirà la gestione digitale delle cellule staminali di Shineco su Ethereum, mentre BICC integrerà i suoi servizi di conservazione di cellule iPSC nel sistema blockchain di Shineco. La collaborazione sfrutta la rete di oltre 3.000 agenti di vendita di BICC e il loro know-how in soluzioni per la guarigione delle ferite, banca del sangue cellulare e tecnologia di rilascio degli esosomi.
Shineco (NASDAQ: SISI) ha formado una alianza estratégica con BICC Pte Ltd, con sede en Singapur, para impulsar su ecosistema de activos celulares basado en blockchain. La colaboración se centra en implementar y canjear "on-chain cell assets" entre múltiples instituciones, marcando la transición de la integración técnica a aplicaciones en el mundo real.
La asociación se apoya en las iniciativas previas de Shineco, incluida la creación de una Cell Digital Division y la adquisición de una participación del 51 % en Xi'an Dong'ao Health Management. Plus Me proporcionará la gestión digital de las células madre de Shineco en Ethereum, mientras que BICC integrará sus servicios de almacenamiento de células iPSC en el sistema blockchain de Shineco. La colaboración aprovecha la red de más de 3.000 representantes de ventas de BICC y su experiencia en soluciones para la cicatrización de heridas, banca celular y tecnología de entrega de exosomas.
Shineco (NASDAQ: SISI)는 싱가포르 소재의 BICC Pte Ltd와 전략적 파트너십을 맺고 블록체인 기반 세포 자산 생태계 발전에 나섭니다. 이번 협력은 여러 기관 간의 "on-chain cell assets" 구현 및 상환에 중점을 두며, 기술 통합에서 실제 적용으로의 전환을 의미합니다.
이번 파트너십은 Shineco가 이전에 추진한 사업들에 기초합니다. 여기에는 Cell Digital Division 설립과 Xi'an Dong'ao Health Management의 51% 지분 인수가 포함됩니다. Plus Me는 Ethereum에서 Shineco의 줄기세포 디지털 관리를 제공하고, BICC는 iPSC 줄기세포 보관 서비스를 Shineco의 블록체인 시스템에 통합합니다. 또한 이번 협력은 BICC의 3,000명 이상 판매 인력 네트워크와 상처 치유 솔루션, 세포 은행 및 엑소좀 전달 기술에 대한 전문성을 활용합니다.
Shineco (NASDAQ: SISI) a conclu un partenariat stratégique avec BICC Pte Ltd, basé à Singapour, pour faire avancer leur écosystème d'actifs cellulaires basé sur la blockchain. La collaboration vise à mettre en œuvre et à racheter des "on-chain cell assets" entre plusieurs institutions, marquant la transition de l'intégration technique vers des applications concrètes.
Le partenariat s'appuie sur les initiatives antérieures de Shineco, notamment la création d'une Cell Digital Division et l'acquisition d'une participation de 51 % dans Xi'an Dong'ao Health Management. Plus Me assurera la gestion numérique des cellules souches de Shineco sur Ethereum, tandis que BICC intégrera ses services de stockage de cellules iPSC au système blockchain de Shineco. La collaboration tire parti du réseau de plus de 3 000 représentants commerciaux de BICC et de leur expertise en solutions de cicatrisation, en banque cellulaire et en technologie de délivrance d'exosomes.
Shineco (NASDAQ: SISI) hat eine strategische Partnerschaft mit dem in Singapur ansässigen BICC Pte Ltd geschlossen, um ihr blockchain-basiertes Zell-Asset-Ökosystem voranzubringen. Die Zusammenarbeit konzentriert sich auf die Implementierung und Einlösung von "on-chain cell assets" über mehrere Institutionen hinweg und markiert den Übergang von technischer Integration zu realen Anwendungen.
Die Partnerschaft baut auf Shinecos bisherigen Initiativen auf, darunter die Einrichtung einer Cell Digital Division und der Erwerb einer 51%-Beteiligung an Xi'an Dong'ao Health Management. Plus Me wird die digitale Verwaltung von Shinecos Stammzellen auf Ethereum übernehmen, während BICC seine iPSC-Zelllagerungsdienste in Shinecos Blockchain-System integrieren wird. Die Zusammenarbeit nutzt BICCs Netzwerk von über 3.000 Vertriebsmitarbeitern sowie deren Expertise in Wundheilungslösungen, Zellbanking und Exosom-Delivery-Technologie.
- Strategic partnership with BICC expands global reach and service capabilities
- Access to BICC's extensive network of 3,000+ sales representatives
- Integration of BICC's validated technologies enhances product portfolio
- 51% acquisition of Xi'an Dong'ao strengthens operational infrastructure
- Complex regulatory compliance requirements across multiple jurisdictions
- Technical challenges in blockchain integration and standardization
- Dependency on multiple partners for ecosystem success
Insights
Shineco's blockchain integration of stem cell assets creates a novel cross-enterprise redemption ecosystem, though technical and regulatory hurdles remain substantial.
Shineco is attempting to create a first-of-its-kind ecosystem that tokenizes stem cell assets on blockchain, enabling cross-enterprise redemption of cell-based treatments. The company has constructed this initiative through three key components: (1) establishing a Cell Digital Division, (2) partnering with Plus Me for blockchain management, and (3) acquiring Xi'an Dong'ao Health for physical storage infrastructure.
The new BICC partnership significantly expands this ecosystem by adding 3,000+ sales representatives and multiple Asian service centers to Shineco's network, potentially solving the logistical challenges of cross-regional cell therapy delivery. The technical implementation involves creating ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers" on Ethereum that represent actual stem cell assets.
This approach represents a novel intersection of regenerative medicine and blockchain technology, but faces substantial execution challenges. Creating compliant digital representations of biological assets requires overcoming complex technical, regulatory, and practical hurdles across multiple jurisdictions. The partnership attempts to address this by dividing responsibilities: Shineco handling cell quality, Plus Me managing blockchain compliance, and BICC providing distribution infrastructure.
While innovative, the initiative's success depends on regulatory acceptance of tokenized biological assets, technical robustness of the blockchain implementation, and market adoption of this complex redemption system. This represents Shineco's strategic pivot from being merely a technical service provider to building global cell economy infrastructure – an ambitious but highly speculative transformation.
This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division,signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a
On the offline support front, Shineco has established a "storage + reinfusion" network through the acquisition of Xi'an Dong'ao Health (specializing in stem cell/immune cell storage and health management). BICC's distribution network (3,000+ sales representatives) will serve as extended nodes of this network, allowing users to complete voucher verification and cell therapy services at BICC's Asian service centers. This addresses the inefficiencies of traditional cross-regional cell service circulation. Additionally, BICC's clinically validated wound-healing solutions, serum-free media patents, cell banking services, iPSC-derived therapies and exosome delivery technology will synergize with Shineco's extracellular vesicle-derived products business, with technical parameters incorporated into the blockchain asset valuation system to enhance the technical endorsement of on-chain assets.
In terms of division of responsibilities, Shineco will focus on cell quality and offline network standardization, while BICC will emphasize user services and scenario integration. Both parties will collaborate with technical partners to adapt on-chain modules and compliance tools, ensuring all initiatives strictly adhere to local regulations and internal risk controls. Shineco assumes full responsibility for cell quality, Plus Me ensures on-chain compliance, and BICC contributes its scientist team and medical resources to participate in standardizing cell assets. The three parties will ensure end-to-end compliance for on-chain cell assets—from storage and circulation to application supporting Shineco's vision of "building a decentralized biological cell marketing ecosystem."
Jennifer Zhan, CEO of Shineco, stated, "The collaboration with BICC will tightly integrate 'standards and scenarios,' exploring verifiable application paths within a compliance framework. Shineco is transitioning from a single technical service provider to a global cell economy infrastructure provider. We welcome more biological cell companies to join the ecosystem and will continue to update on project progress."
About BICC Pte Ltd
Founded in 2024, BICC is an innovative biotechnology holding company that unites a world-class team of scientists and medical experts specializing in stem cell treatments and artificial intelligence. With a strategic presence across Asia—including offices in
About Shineco, Inc.
Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information about Shineco, please visit www.biosisi.com/.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "forecast," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco,Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
View original content:https://www.prnewswire.com/news-releases/shineco-nasdaq-sisi--bicc-from-tech-on-chain-to-global-redeemabilityrwa-ecosystem-takes-off-for-long-term-growth-302538261.html
SOURCE Shineco,Inc.
FAQ
What is the strategic partnership between Shineco (NASDAQ: SISI) and BICC?
How will BICC's network benefit Shineco's operations?
What is Shineco's role in the partnership with BICC?
How does the blockchain integration work in Shineco's cell asset system?
What recent acquisitions has Shineco (SISI) made to strengthen its position?
